National Center for Advancing Translational Sciences

New patient contact registry for rare eosinophilic gastrointestinal diseases

Wednesday, March 4, 2015

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) has launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases. The registry is located at www.rdcrn.org/CEGIR. Its purpose is to create a single, international database with information submitted by patients with EGID and their families. The database will enable CEGIR investigators to identify and recruit patients with EGID for new research studies for improving treatments and clinical care.

[Read More]

NIH awards $5.9M in grants for frontotemporal degeneration research

Wednesday, October 29, 2014

The NIH will award three large, five-year projects on a specific form of dementia, known as frontotemporal because of the areas of the brain that are affected. The projects, funded by the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA) and the National Center for Advancing Translational Sciences (NCATS), will receive more than $5.9 million for 2014.

[Read More]

aTyr Pharma appoints John C. McKew vice president, research

Thursday, October 23, 2014

aTyr Pharma, an innovative rare disease therapeutics enterprise, has announced that John C. McKew, Ph.D., has joined the company as vice president, research. McKew brings more than two decades of experience in translational research, including key leadership positions at the NIHWyeth Research and Genetics Institute (prior to its acquisition by Wyeth). McKew will lead aTyr’s efforts to expand and translate its novel Physiocrine biology into meaningful therapeutics to treat rare, grave immune-driven disorders.

[Read More]